| Literature DB >> 32198425 |
Jeremy E Turnbull1,2, Weston B Struwe3, Kevin Pagel4,5, Rebecca L Miller6,7,8, Scott E Guimond2,9, Ralf Schwörer10, Olga V Zubkova10, Peter C Tyler10, Yongmei Xu11, Jian Liu11, Pradeep Chopra12, Geert-Jan Boons12,13, Márkó Grabarics4,5, Christian Manz4,5, Johanna Hofmann4,5, Niclas G Karlsson14.
Abstract
Despite evident regulatory roles of heparan sulfate (HS) saccharides in numerous biological processes, definitive information on the bioactive sequences of these polymers is lacking, with only a handful of natural structures sequenced to date. Here, we develop a "Shotgun" Ion Mobility Mass Spectrometry Sequencing (SIMMS2) method in which intact HS saccharides are dissociated in an ion mobility mass spectrometer and collision cross section values of fragments measured. Matching of data for intact and fragment ions against known values for 36 fully defined HS saccharide structures (from di- to decasaccharides) permits unambiguous sequence determination of validated standards and unknown natural saccharides, notably including variants with 3O-sulfate groups. SIMMS2 analysis of two fibroblast growth factor-inhibiting hexasaccharides identified from a HS oligosaccharide library screen demonstrates that the approach allows elucidation of structure-activity relationships. SIMMS2 thus overcomes the bottleneck for decoding the informational content of functional HS motifs which is crucial for their future biomedical exploitation.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32198425 PMCID: PMC7083916 DOI: 10.1038/s41467-020-15284-y
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 14.919
Fig. 1Graphic depiction of the SIMMS2 strategy for de novo sequencing of HS saccharides.
a Heparin and HS contain variant domains including unmodified acetylated domains (with high levels of GlcNAc residues), transition domains (GlcNAc and GlcNS containing residues), and sulfated domains (high levels of GlcNS and O-sulfation). A library of shorter oligosaccharide standards were generated. b Illustration of MS and MS/MS to provide mass and the ability of ion mobility mass spectrometry (IMMS) to provide a third dimension that distinguishes isomers with collision cross section (CCS) values. c The availability of MS, MS/MS, and IMMS data from a library of known standards (a, b) then allows a strategy for unambiguous sequencing of undefined oligosaccharides based on comparison with standards. d Illustration of the iterative loop process for expansion of the CCS dataset necessary to further develop the SIMMS2 strategy.
Fig. 2Drift tube ion mobility separation (DTIMS) of isomeric HS standards.
Intact HS standards were subjected to DTIMS to define collision cross section (CCS) values. Variant degrees of separation were observed for (a), Disaccharides ΔUA-GlcNAc6S (#2) and ΔUA2S-GlcNAc (#7). b Tetrasaccharides GlcA-GlcNAc6S-GlcA-GlcNAc6S-R1 (#9) and IdoA-GlcNAc6S-IdoA-GlcNAc6S-R1 (#10), where R1 is (CH2)5NH2. c Octasaccharides GlcNAc6S-[IdoA-GlcNAc6S]3-IdoA-R2 (#19) and GlcNAc6S-[GlcA-GlcNAc6S]3-GlcA-R2 (#20), where R2 is C7H7O. d Decasaccharides GlcNAc6S-[IdoA-GlcNAc6S]4-IdoA-R2 (#27) and GlcNAc6S-[GlcA-GlcNAc6S]4-GlcA-R2 (#28), where R2 is C7H7O. Full details of structures and CCS values are provided in Supplementary Tables 1 and 2.
Fig. 3Using the SIMMS2 method for sequencing a hexasaccharide.
Overlaying two tetrasaccharide standard structures (#12 and #14) provides complete sequence coverage of the hexasaccharide (#16). Each structure was fragmented in the trap of the mass spectrometer and analyzed using drift tube ion mobility mass spectrometry (DTIMS), resulting in accurate collision cross section (CCS) values. A comparison of overlapping fragment ions displayed the same CCS value between the two tetra- and hexasaccharides, providing a three-dimensional (MS, MS/MS and IMMS) sequencing method. a–f The hexasaccharide displays the DTIMS data to be determined. g, h Tetrasaccharide #12 displayed CCS values from B ions; B2—135 Å2 and B3—160 Å2 matched CCS values observed in the hexasaccharide (a–c). i, j Tetrasaccharide #14 displayed CCS values from Y ions; Y2 156 Å2 and Y3 213 Å2 matched the CCS values observed in the hexasaccharide (d–f).
Fig. 4MS2 sequencing of two 9mer saccharides.
HS structures #25 and #26 were fragmented in the trap and separated through IMMS to create a defined set of CCS values for each fragment. IMMS of fragments (a) represent B ion fragments from #25, and #26, indicating that the 2O-sulfate is on the IdoA at position 5. Fragment ions from B/Y/C/Z are displayed in Supplementary Tables 15 and 16. b Radar chart illustration of BaF3 cell activation and inhibition assays of HS structures #25 and #26. Activation (cell proliferation) assays were performed with fibroblast growth factor 1 (FGF1) or FGF2 (1 ng/mL) and standards #25/26. Heparin (3 μg/mL) was used as positive control, while FGF1 or FGF2 alone was used as negative control. Inhibition assays were performed with the same compounds (3 μg/mL) in the presence of a sub-maximal dose of heparin (0.1 μg/mL). Cell proliferation results were expressed as a percentage of heparin activity set as 100%. Data for panel b are presented as mean ± standard deviation, n = 3. Source data are provided as a Source Data file.
Fig. 5Applying the SIMMS2 method for sequencing HS motifs displaying FGF bioactivity.
a SIMMS2 sequencing of hexasaccharides #HS1 and #HS2 through the comparison of B ion fragment CCS values from standard #30 and #36. b BaF3 FGF2 inhibition assay with a sub-maximal dose of heparin (0.1 μg/mL) in the presence of serially diluted #HS1 (black circle with line) and #HS2 (white circle with line) saccharides. Data for (b) are presented as mean ± standard deviation, n = 3. Source data are provided as a Source Data file.